Scholarlink

<p>Tuberculosis (TB) remains the foremost cause of death from infectious diseases globally, prompting ongoing efforts to improve treatment options. This includes developing compounds with novel modes of action and identifying optimal treatment regimens that allow for treatment shortening. One promising strategy involves targeting cytochrome <i>bc</i><sub>1</sub> oxidase in <i>Mycobacterium tuberculosis</i>, a key enzyme in the respiratory chain. In this study, we evaluate the potential of cytochrome <i>bc</i><sub>1</sub> inhibitors as partner drugs in TB combination regimens. Using a relapsing mouse model, we demonstrate that these inhibitors enhance regimen sterilisation and significantly reduce the time required for effective treatment. We also propose several novel combination strategies for both multidrug-resistant and drug-sensitive TB, where cytochrome <i>bc</i><sub>1</sub> inhibitors contribute to sterilisation and improved treatment outcomes. Furthermore, <i>M. tuberculosis</i> clinical isolates exhibited heightened susceptibility to cytochrome <i>bc</i><sub>1</sub> inhibitors compared to laboratory-adapted strains, highlighting the importance of using clinical isolates in TB drug discovery to better reflect the diversity of TB populations. These findings emphasise the potential of cytochrome <i>bc</i><sub>1</sub> inhibition in the development of more effective and shorter treatment regimens for TB, supporting the need for further clinical investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Clara Aguilar-Pérez,
  • Anne J. Lenaerts,
  • Cristina Villellas,
  • Jerome Guillemont,
  • John Dallow,
  • Hannah Painter,
  • Nicole C. Ammerman,
  • Anis Hassan,
  • Guillaume Golovkine,
  • Laure Brock,
  • Sylvie Sordello,
  • Aurélie Chauffour,
  • Alexandra Aubry,
  • Thi Cuc Mai,
  • Sarah Wong,
  • Taane G. Clark,
  • Kiyean Nam,
  • Jeongjun Kim,
  • Jinho Choi,
  • Marjolein Crabbe,
  • Jorge Esquivias,
  • Nacer Lounis,
  • Bart Stoops,
  • Katie Amssoms,
  • Jose M. Bartolome-Nebreda,
  • Veronica Gruppo,
  • Gregory T. Robertson,
  • Nicolas Veziris,
  • Anna M. Upton,
  • Eric L. Nuermberger,
  • Vivian Cox,
  • Lluis Ballell,
  • Benny Baeten,
  • Anil Koul,
  • Alexander S. Pym,
  • Richard J. Wall,
  • Dirk A. Lamprecht

摘要

Tuberculosis (TB) remains the foremost cause of death from infectious diseases globally, prompting ongoing efforts to improve treatment options. This includes developing compounds with novel modes of action and identifying optimal treatment regimens that allow for treatment shortening. One promising strategy involves targeting cytochrome bc1 oxidase in Mycobacterium tuberculosis, a key enzyme in the respiratory chain. In this study, we evaluate the potential of cytochrome bc1 inhibitors as partner drugs in TB combination regimens. Using a relapsing mouse model, we demonstrate that these inhibitors enhance regimen sterilisation and significantly reduce the time required for effective treatment. We also propose several novel combination strategies for both multidrug-resistant and drug-sensitive TB, where cytochrome bc1 inhibitors contribute to sterilisation and improved treatment outcomes. Furthermore, M. tuberculosis clinical isolates exhibited heightened susceptibility to cytochrome bc1 inhibitors compared to laboratory-adapted strains, highlighting the importance of using clinical isolates in TB drug discovery to better reflect the diversity of TB populations. These findings emphasise the potential of cytochrome bc1 inhibition in the development of more effective and shorter treatment regimens for TB, supporting the need for further clinical investigation.